MARK2 and acute myeloid leukemia: Adipogenesis of bone marrow mesenchymal stem cells (MSCs) promotes chemoresistance in AML cells, and METTL3 can significantly inhibit MSC adipogenesis by mediating m6A modification to affect AKT Serine/Threonine Kinase (Akt1) mRNA and reduce Akt protein expression in MSCs [143] and improve drug resistance in AML MSCs.